Fig. 3

Tumor burden alters the fate of myeloid progenitors. a CD45.1⁺Lin⁻Sca1⁻cKit⁺ MPs were transferred into mice bearing 1.0 cm diameter orthotopic PyMT-B6 tumors or tumor-free controls. BM was analyzed for CD45.1⁺ populations after 2 weeks. BM MDPs, CDPs, pre-DCs, CD24⁺ cDC1s, and granulocytes, and blood granulocytes displayed as frequency of CD45.1; n = 5/group. b CD45.2⁺Lin⁻Sca1⁻cKit⁺ MPs, CD45.2⁺ MDPs, and CD45.2⁺ CDPs were isolated from end-stage orthotopic PyMT-B6 tumor-bearing or tumor-free donors. Progenitors were cultured on CD45.1⁺ BM feeder culture for 5 days in the presence of 100 ng/ml Flt3L. Final cultures were analyzed for cDC1 (Live CD45.2⁺CD45.1^-MHCII⁺CD11c⁺Sirpα^-CD24⁺). End stage is defined in the Methods. Data are representative of three independent experiments consisting of three wells per condition. GMPs, MDPs, and CDPs were sorted from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-free controls. c GMPs, MDPs, and CDPs were analyzed by RT-qPCR. d MDPs and CDPs were analyzed by microarray. Cluster analysis was performed with a differential genes list generated from gene with 1.5-fold at p < 0.05 and FDR q < 0.05 in MDP or CDP comparison from PyMT-B6 tumor bearing to tumor free. Four samples, each consisting of two mice, were analyzed per group. e MDPs and CDPs were isolated from PyMT-B6 tumor-bearing mice or tumor-free controls. Progenitors were adoptively transferred into BATF3^−/− mice. PyMT-mCh-OVA was implanted after 3 days into wild-type mice, BATF3^−/− mice without adoptive transfer, and BATF3^−/− mice with adoptive transfer from tumor-free or tumor-bearing mice. Tumor growth was monitored. Error bars represent mean +/− s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-sided Student’s t test or two-way ANOVA